Real-world use of oral versus subcutaneous semaglutide in a cohort of type 2 diabetic patients: which option to which patient?
Journal of Endocrinological Investigation · 2024
DOI: 10.1007/s40618-024-02369-4 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Endocrinological Investigation, 2024. Verfasst von C Formichi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes and Metabolic Diseases Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100, Siena, Italy. caterina.formichi@…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Hypoglycemic Agents. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero dell'Istruzione, dell'Università e della Ricerca, Università degli Studi di Siena.
Abstract (Originalsprache)
Purpose
To evaluate the variables influencing the therapeutic choice toward oral versus subcutaneous semaglutide in a cohort of diabetic subjects.
Methods
We retrospectively collected data of 292 patients followed at the Diabetes Unit of the University Hospital of Siena and the Hospital of Grosseto, who were prescribed oral (n = 115) or subcutaneous (n = 177) semaglutide between October 2021 and October 2022.
Results
Oral semaglutide was preferentially prescribed in older subjects with longer disease duration in replacement of other antidiabetic drugs, while subcutaneous semaglutide was preferentially prescribed in add-on to metformin in subjects with higher body weight and BMI. After 6 months, both formulations significantly improved glycemic control and body weight, however injectable semaglutide showed a greater efficacy on A1c levels, weight loss, BMI and waist circumference reduction. No differences were found in terms of adverse events.
Conclusion
In our experience, injectable semaglutide is preferred in patients with excess weight and shorter disease duration, while the oral formulation was used later and especially after therapeutic failure of previous therapies. Follow-up data indicate similar tolerability and efficacy of both formulations, despite subcutaneous semaglutide demonstrated greater efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Diabetes and Metabolic Diseases Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100, Siena, Italy. caterina.formichi@unisi.it.
- Fondazione Umberto Di Mario, Toscana Life Science, 53100, Siena, Italy. caterina.formichi@unisi.it.
- Metabolic Diseases and Diabetes Unit, Misericordia Hospital, USL Toscana sud est, 58100, Grosseto, Italy.
- Fondazione Umberto Di Mario, Toscana Life Science, 53100, Siena, Italy.
- Diabetes and Metabolic Diseases Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, 53100, Siena, Italy.
Förderung
- Ministero dell'Istruzione, dell'Università e della Ricerca
- Università degli Studi di Siena
Zitieren
APA
Formichi, C., Baronti, W., de Gennaro, G., Cerrai Ceroni, M., Nigi, L., Rizzo, L., & Dotta, F. (2024). Real-world use of oral versus subcutaneous semaglutide in a cohort of type 2 diabetic patients: which option to which patient?. Journal of Endocrinological Investigation. https://doi.org/10.1007/s40618-024-02369-4
Vancouver
Formichi C, Baronti W, de Gennaro G, Cerrai Ceroni M, Nigi L, Rizzo L, et al. Real-world use of oral versus subcutaneous semaglutide in a cohort of type 2 diabetic patients: which option to which patient?. Journal of Endocrinological Investigation. 2024. doi:10.1007/s40618-024-02369-4
BibTeX
@article{Formichi2024,
author = {Formichi, C and Baronti, W and de Gennaro, G and Cerrai Ceroni, M and Nigi, L and Rizzo, L and Dotta, F},
title = {Real-world use of oral versus subcutaneous semaglutide in a cohort of type 2 diabetic patients: which option to which patient?},
journal = {Journal of Endocrinological Investigation},
year = {2024},
doi = {10.1007/s40618-024-02369-4}
}
EUVIMED